Comparison · NCT00454779-sae
Panitumumab Plus Chemotherapy vs Chemotherapy Alone: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Panitumumab Plus Chemotherapy vs Chemotherapy Alone: serious adverse events. Trial comparisons, record NCT00454779-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00454779-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.607 | 0.476 | 0.724 | wilson | |
| Risk in group 2 | 0.491 | 0.364 | 0.619 | wilson | |
| Risk difference, group 1 minus group 2 | 0.116 | -0.067 | 0.289 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.24 | 0.879 | 1.74 | log | |
| Odds ratio, group 1 over group 2 | 1.6 | 0.755 | 3.4 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Panitumumab Plus Chemotherapy than on Chemotherapy Alone | 8.6 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Panitumumab Plus Chemotherapy | Panitumumab + Docetaxel + Cisplatin, experiment | 34 | 56 | EG000 |
| Group 2 | Chemotherapy Alone | Docetaxel + Cisplatin, control | 27 | 55 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date of the first-line treatment. The median time frame is 4.5 months for Panitumumab Plus Chemotherapy arm and 4.4 months for Chemotherapy Alone arm.
Source ClinicalTrials.gov
Trial
- Title
- PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response
- NCT number
- NCT00454779
- Phases
- PHASE2
- Conditions
- Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck
- Interventions
- Cisplatin, Panitumumab, Docetaxel, Cisplatin, Docetaxel
- Lead sponsor
- Amgen
- Results first posted
- 2014-02-07
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00454779?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00454779-sae